Citation only
via OpenAlex
Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets · 2011 · ▲ 166 citations
Abstract
Recent meta-analyses have revealed that the risk of bone fracture is increased in both type 1 and type 2 diabetic patients. Low bone mineral density (BMD) can not necessarily explain the link, because BMD is increased rather than decreased in type 2 diabetes, while it is consistently low in type 1 diabetes subjects. Although multiple factors could influence the quality of bone and increase the bone fragility in diabetes, there is accumulating evidence for the association between osteoporosis and vascular calcification, which is an independent predictor of cardiovascular disease morbidity and mortality. Advanced glycation end products (AGEs) are formed by a non-enzymatic reaction between aldehydes of reducing sugars and the amino groups of proteins, lipids and nucleic acids that could contribute to the aging of macromolecules. The formation and accumulation of AGEs have been known to progress at an accelerated rate under diabetes. There is a growing body of evidence that AGEs and their receptor (RAGE) system elicit oxidative stress generation and subsequently evoke inflammatory responses in vascular wall cells, osteoblasts and osteoclasts, thereby being involved in both vascular calcification and osteoporosis in diabetes. Further, cross-linking in the organic bone matrix by AGEs could adversely affect the fracture resistance of bone. Therefore, in this paper, I review the pathophysiological role of the AGEs-RAGE-oxidative stress system in decreased BMD and increased bone fragility in diabetes. I also discuss here the potential therapeutic interventions of the AGEs-RAGE axis for preventing osteoporosis in diabetes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2174/138945011798829456
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Yamagishi, S. (2011). Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes. <em>Current Drug Targets</em>. https://doi.org/10.2174/138945011798829456
Vancouver
Yamagishi S. Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes. Current Drug Targets. 2011. doi:10.2174/138945011798829456.
BibTeX
@article{shoichi2011Roleof,
title = {Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes},
author = {Sho‐ichi Yamagishi},
journal = {Current Drug Targets},
year = {2011},
doi = {10.2174/138945011798829456},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomolecules 2015
Open access · CC-BY
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Chinese Journal of Osteoporosis 2002
Citation only
Relationship between bone mineral density, age and bone metabolic markers in old male patients with type 2 diabetes mellitus
Gerontology 2012
Open access · OA
Molecular Basis of Arterial Stiffening: Role of Glycation – A Mini-Review
Diabetes/Metabolism Research and Reviews 2001
Open access · OA
The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes Society
Journal of Endocrinological Investigation 2010
Citation only
Age-related bone mineral density, osteoporosis rate and risk of vertebral fracture in mainland Chinese women with type 2 diabetes mellitus
Oxidative Medicine and Cellular Longevity 2020
Open access · CC-BY